奥拉西坦治疗脑卒中临床效果评价及药理分析

Clinical evaluation and pharmacological analysis of oxiracetam in stroke

目的分析奥拉西坦在脑卒中患者治疗中的临床效果,探讨其药理特性及作用机制。方法将我院2014年2月~2017年10月收治的336例脑卒中患者随机分成ABC三组,每组112例,在常规治疗的基础上,A组给予吡拉西坦注射液治疗,B组给予奥拉西坦注射液治疗,C组给予奥拉西坦+尼莫地平注射液治疗,按照NIHSS评分/Barthel指数统计分析,对比三组治疗前后效果。结果治疗前三组NIHSS评分/Barthel指数比较,差异无统计学意义(P>0.05);三组治疗后NIHSS评分/Barthel指数分别低于/高于相应各组治疗前相对应的评分/指数,差异有统计学意义(P<0.05);B组治疗后NIHSS评分/Barthel指数分别低于/高于A组治疗后相对应的评分/指数,差异有统计学意义(P<0.05);C组治疗后NIHSS评分/Barthel指数分别低于/高于B组治疗后相对应的评分/指数,差异有统计学意义(P<0.05);三组不良反应发生率对比差异无统计学意义(P>0.05)。结论奥拉西坦在治疗脑卒中患者中能有效减轻患者神经功能缺损并提升日常生活能力,效果优于吡拉西坦,联用尼莫地平疗效更佳。

Objective To analyze the clinical efficacy of oxiracetam in stroke and to explore its pharmacological characteristics and mechanism of action. Methods A total of 336 stroke patients admitted from February 2014 to October 2017 in our hospital were randomly divided into three groups（n=112）.On the basis of routine treatment,group A was given Piracetam,group B was given oxiracetam injection, group C was given oxiracetam plus nimodipine,and according to NIHSS score/Barthel index statistical analysis,the before and after treatment effect of three groups were compared. Results There was no significant difference in the NIHSS score/Barthel index between the three groups before treatment（P 0.05）.The NIHSS score/Barthel index of the three groups after treatment were lower/higher than the corresponding scores/indices before treatment（P 0.05）.The NIHSS score/Barthel index of group B after treatment were lower/higher than that of group A after treatment respectively,with significant difference（P 0.05）.The NIHSS score/Barthel index in group C after treatment were lower/higher than those in group B after treatment, with significant difference（P 0.05）.There was no significant difference in the incidence of adverse reactions among the three groups（P 0.05）. Conclusion Oxiracetam can effectively reduce the neurological deficit and improve the daily living ability in patients with stroke.The effect of oxiracetam is better than that of piracetam,and the combination of nimodipine is better.